COMP <GO>
ALKS vs ABBV // GROSS PROFIT MARGIN
Alkermes plc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ALKS 7
— ABBV 7
▲ GROSS PROFIT MARGIN LEADER: ALKS
LAST: $45.34 (-0.07%) • MKT CAP: $7.61B
gross-margins
86.70%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 86.70% | 70.20% | +16.50 | ALKS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | 29.00% | -15.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.1x | 33.3x | -8.20 | ALKS | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | 3.47% | +2.84 | ALKS | /fcf-yield <GO> |
| Operating Margin | 17.20% | 24.60% | -7.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 16.40% | 6.90% | +9.50 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 8.60% | -13.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 5.33 | +2.70 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | ALKS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.1 | 72.8 | -11.65 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 113.1x | -83.80 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $513.86B | -$506.25B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | ABBV REV | ALKS GROSS % | ABBV GROSS % | ALKS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $61.16B | 86.7% | 70.2% | $480.3M | $17.82B |
| FY 2024 | $1.56B | $56.33B | 84.2% | 70.0% | $405.6M | $17.83B |
| FY 2023 | $1.66B | $54.32B | 44.0% | 44.0% | $326.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
ABBV // BETA 1.15